PAVmed Inc. entered into subscription agreements for the private placement of 13,625 series A convertible preferred stock at an issue price of $1,000 per share for gross proceeds of $13,625,000 on March 7, 2023. The transaction included participation certain accredited investors. In connection with the offering the company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock with the Secretary of State of the State of Delaware.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.83 USD | +2.23% | -4.69% | -55.58% |
May. 14 | Transcript : PAVmed Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 07 | Pavmed Inc. Appoints Dennis Matheis to Board of Directors | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.58% | 16.88M | |
+11.91% | 227B | |
+15.46% | 197B | |
+18.58% | 141B | |
+30.36% | 110B | |
+0.65% | 64.15B | |
+17.74% | 53.72B | |
+5.82% | 51.75B | |
+11.23% | 45.2B | |
+5.73% | 37.37B |
- Stock Market
- Equities
- PAVM Stock
- News PAVmed Inc.
- PAVmed Inc. announced that it has received $13.625 million in funding